Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Cyclacel Pharmaceuti (NASDAQ: CYCC)

$5.11 USD -$0.29 (-5.37%)
Last Price $5.11
Net Change $-0.29 (-5.37%)
Bid $5.25
Ask Price $5.69
Open Price $5.23
Previous Close Price $5.4
High Price $5.43
Low Price $5.04
Number of Trades 566
Volume 173,200
Fifty Two Week High $10.9 (2017-04-04)
Fifty Two Week Low $3.05 (2016-11-08)
Average Daily Volume 694,514
Share Outstanding 4,270 Shares
Total Dividend Payout 0.15/yr
Dividend Yield 2.78%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $35.71
Recent Earnings $
Annual EPS $-4.84
Last Quarter EPS $
Market Capitalization $0.02B
Insider Shareholders % 0.04%
Annual Revenue $0B
No. Shares Outstanding 4,270
Inst. Shareholder % 16.2%
Annual Net Income $0B
TTM Net Profit Margin $100.09
1-Year Return -0.4%
3-Year Return -87.18%
5-Year Return -89.01%
5-Year Revenue Growth 20%
5-Year Earnings Growth -86.98%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 2.56%
Change in EPS YTD 35.709999%
Dividends per Share $0.15
Stock Split Ratio 1-12
Beta 3.01
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

CYCC News & Stock Updates